Dermatology · Phase 2-3 · pulled 2026-11-06

Atopic dermatitis: trial sites and investigators

25 sites and 10 investigators from 300 completed and terminated Phase 2-3 trials of atopic dermatitis (last 12 years), plus 122 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Atopic dermatitis: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	First OC Dermatology Fountain Valley, United States · 9 spellings merged	39 31 completed, 8 terminated	NCT05882877 NCT06881251 NCT06015308 6 trials with titles NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT06881251 A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) terminated 2026-04-07 Stop reason on the record: “Terminated: futility criteria met at interim efficacy analysis.” NCT06015308 A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo completed 2026-01-16 NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT06130566 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis completed 2025-11-13 NCT06238817 A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis completed 2025-10-17	2026-07-01	8 NCT07783425 NCT06863961 NCT07230860 NCT05492578	88
2	Dawes Fretzin Clinical Research Group, LLC Indianapolis, United States · 6 spellings merged	36 28 completed, 8 terminated	NCT05882877 NCT06881251 NCT03422822 6 trials with titles NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT06881251 A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) terminated 2026-04-07 Stop reason on the record: “Terminated: futility criteria met at interim efficacy analysis.” NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT05704738 A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) completed 2025-11-25 NCT06224348 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids completed 2025-11-01 NCT06436183 A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis completed 2025-08-12	2026-07-01	9 NCT07783425 NCT06807281 NCT07230860 NCT05995964	90
3	The Indiana Clinical Trials Center Plainfield, United States · 8 spellings merged	30 25 completed, 5 terminated	NCT05882877 NCT06790121 NCT03422822 6 trials with titles NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT06790121 A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis completed 2026-04-09 NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT05704738 A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) completed 2025-11-25 NCT06810050 Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis completed 2025-10-30 NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) completed 2025-04-22	2026-07-01	1 NCT07105488	93
4	Progressive Clinical Research San Antonio, United States · 6 spellings merged	27 19 completed, 8 terminated	NCT07150845 NCT06790121 NCT06881251 6 trials with titles NCT07150845 Phase 2b Study of EVO756 in Adults With Atopic Dermatitis completed 2026-08-03 NCT06790121 A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis completed 2026-04-09 NCT06881251 A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) terminated 2026-04-07 Stop reason on the record: “Terminated: futility criteria met at interim efficacy analysis.” NCT06181435 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2) completed 2026-03-12 NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) completed 2025-04-22 NCT05911841 A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis terminated 2025-03-14 Stop reason on the record: “The decision to terminate the study was due to efficacy/effectiveness reasons.”	2026-08-03	4 NCT07230860 NCT07599813 NCT07105488 NCT05509023	87
5	Center for Dermatology Clinical Research, Inc. Fremont, United States · 5 spellings merged	26 23 completed, 3 terminated	NCT07150845 NCT05704738 NCT06810050 6 trials with titles NCT07150845 Phase 2b Study of EVO756 in Adults With Atopic Dermatitis completed 2026-08-03 NCT05704738 A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) completed 2025-11-25 NCT06810050 Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis completed 2025-10-30 NCT06923228 A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis completed 2025-09-30 NCT06436183 A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis completed 2025-08-12 NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) completed 2025-04-22	2026-08-03	1 NCT06397911	94
6	Lynderm Research Inc. Markham, Canada · 3 spellings merged	26 20 completed, 6 terminated	NCT05882877 NCT06881251 NCT06224192 6 trials with titles NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT06881251 A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) terminated 2026-04-07 Stop reason on the record: “Terminated: futility criteria met at interim efficacy analysis.” NCT06224192 A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis completed 2026-03-16 NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT05704738 A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) completed 2025-11-25 NCT06238817 A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis completed 2025-10-17	2026-07-01	2 NCT06863961 NCT07223697	89
7	Dermatology Research Associates Los Angeles, United States	25 20 completed, 5 terminated	NCT05882877 NCT06224192 NCT05633355 6 trials with titles NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT06224192 A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis completed 2026-03-16 NCT05633355 A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) completed 2025-07-31 NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) completed 2025-04-22 NCT05911841 A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis terminated 2025-03-14 Stop reason on the record: “The decision to terminate the study was due to efficacy/effectiveness reasons.” NCT05372419 A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color completed 2025-02-17	2026-07-01	2 NCT07599813 NCT05559359	89
8	Peking University People's Hospital Beijing, China · 4 spellings merged	24 22 completed, 2 terminated	NCT07330934 NCT06280716 NCT05882877 6 trials with titles NCT07330934 A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis terminated 2026-08-18 Stop reason on the record: “Sponsor Decision” NCT06280716 A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis completed 2026-07-16 NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT05676242 A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis completed 2026-03-12 NCT06477835 A Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Severe Atopic Dermatitis completed 2025-12-23 NCT06116565 A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis completed 2025-11-26	2026-08-18	10 NCT07216027 NCT06931990 NCT07370909 NCT07784816	98
9	Innovaderm Research Inc. Montreal, Canada · 4 spellings merged	24 18 completed, 6 terminated	NCT05882877 NCT06881251 NCT03422822 6 trials with titles NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT06881251 A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) terminated 2026-04-07 Stop reason on the record: “Terminated: futility criteria met at interim efficacy analysis.” NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT06101823 Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis) completed 2025-08-18 NCT05398445 A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) completed 2025-01-13 NCT05724199 A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) completed 2024-12-04	2026-07-01	1 NCT07783425	89
10	ForCare Clinical Research Tampa, United States · 5 spellings merged	23 19 completed, 4 terminated	NCT03422822 NCT04392154 NCT05906628 6 trials with titles NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) completed 2025-04-22 NCT05906628 Topical Ruxolitinib Evaluation in Chronic Hand Eczema completed 2024-12-13 NCT05399368 An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis terminated 2024-05-24 Stop reason on the record: “Study on clinical hold by FDA” NCT04921969 A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3) completed 2024-04-08 NCT05158023 Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis completed 2023-09-05	2025-12-22	2 NCT05995964 NCT05559359	91
11	Center for Clinical Studies Houston, United States · 10 spellings merged	22 18 completed, 4 terminated	NCT05882877 NCT06881251 NCT06181435 6 trials with titles NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT06881251 A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) terminated 2026-04-07 Stop reason on the record: “Terminated: futility criteria met at interim efficacy analysis.” NCT06181435 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2) completed 2026-03-12 NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT06238817 A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis completed 2025-10-17 NCT06436183 A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis completed 2025-08-12	2026-07-01	1 NCT07230860	88
12	Clinical Science Institute Santa Monica, United States	21 17 completed, 4 terminated	NCT05882877 NCT03422822 NCT05704738 6 trials with titles NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT05704738 A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) completed 2025-11-25 NCT05372419 A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color completed 2025-02-17 NCT05369403 A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab completed 2025-02-05 NCT05651711 A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) completed 2024-08-27	2026-07-01	1 NCT07216027	91
13	Fachklinik Bad Bentheim Bad Bentheim, Germany · 5 spellings merged	20 16 completed, 4 terminated	NCT05882877 NCT06881251 NCT03422822 6 trials with titles NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT06881251 A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) terminated 2026-04-07 Stop reason on the record: “Terminated: futility criteria met at interim efficacy analysis.” NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT05704738 A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) completed 2025-11-25 NCT06238817 A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis completed 2025-10-17 NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) completed 2025-04-22	2026-07-01	6 NCT07223697 NCT05995964 NCT07599813 NCT06832618	90
14	Centrum Medyczne Angelius Provita Katowice, Poland	19 16 completed, 3 terminated	NCT05882877 NCT06881251 NCT03422822 6 trials with titles NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT06881251 A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) terminated 2026-04-07 Stop reason on the record: “Terminated: futility criteria met at interim efficacy analysis.” NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT05704738 A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) completed 2025-11-25 NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) completed 2025-04-22 NCT05398445 A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) completed 2025-01-13	2026-07-01	3 NCT07216027 NCT05995964 NCT06807268	90
15	MediSearch Clinical Trials Saint Joseph, United States · 7 spellings merged	18 17 completed, 1 terminated	NCT07150845 NCT06790121 NCT03422822 6 trials with titles NCT07150845 Phase 2b Study of EVO756 in Adults With Atopic Dermatitis completed 2026-08-03 NCT06790121 A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis completed 2026-04-09 NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT05704738 A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) completed 2025-11-25 NCT06130566 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis completed 2025-11-13 NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) completed 2025-04-22	2026-08-03	2 NCT06832618 NCT07105488	94
16	National Taiwan University Hospital Taipei, Taiwan	18 16 completed, 2 terminated	NCT05882877 NCT03952559 NCT03422822 6 trials with titles NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT03952559 A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis completed 2026-05-22 NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT05704738 A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) completed 2025-11-25 NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) completed 2025-04-22 NCT05911841 A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis terminated 2025-03-14 Stop reason on the record: “The decision to terminate the study was due to efficacy/effectiveness reasons.”	2026-07-01	3 NCT07230860 NCT05559359 NCT06397911	96
17	Veracity Clinical Research Woolloongabba, Australia · 2 spellings merged	18 16 completed, 2 terminated	NCT05882877 NCT03952559 NCT03422822 6 trials with titles NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT03952559 A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis completed 2026-05-22 NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT06238817 A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis completed 2025-10-17 NCT05633355 A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) completed 2025-07-31 NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) completed 2025-04-22	2026-07-01	2 NCT05559359 NCT06855745	94
18	Arlington Research Center, Inc Arlington, United States · 6 spellings merged	18 16 completed, 2 terminated	NCT06181435 NCT03422822 NCT04392154 6 trials with titles NCT06181435 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2) completed 2026-03-12 NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) completed 2025-04-22 NCT05372419 A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color completed 2025-02-17 NCT05571943 A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis completed 2024-07-31 NCT05399368 An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis terminated 2024-05-24 Stop reason on the record: “Study on clinical hold by FDA”	2026-03-12	5 NCT07783425 NCT06863961 NCT05492578 NCT06241118	91
19	Revival Research Institute, LLC Troy, United States · 7 spellings merged	17 12 completed, 5 terminated	NCT07150845 NCT05882877 NCT03422822 6 trials with titles NCT07150845 Phase 2b Study of EVO756 in Adults With Atopic Dermatitis completed 2026-08-03 NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT06238817 A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis completed 2025-10-17 NCT06436183 A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis completed 2025-08-12 NCT04684485 To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis completed 2025-03-18	2026-08-03	7 NCT07783425 NCT06863961 NCT07223697 NCT05995964	85
20	Hangzhou First People's Hospital Hangzhou, China · 17 spellings merged	17 16 completed, 1 terminated	NCT06280716 NCT05882877 NCT07712536 6 trials with titles NCT06280716 A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis completed 2026-07-16 NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT07712536 Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis completed 2025-12-19 NCT05704738 A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) completed 2025-11-25 NCT06173284 Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis completed 2025-11-20 NCT06700499 A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis completed 2025-09-11	2026-07-16	9 NCT07895615 NCT07767253 NCT07782476 NCT07598383	99
21	The Second Xiangya Hospital of Central South University Changsha, China · 14 spellings merged	17 15 completed, 2 terminated	NCT06280716 NCT05882877 NCT03422822 6 trials with titles NCT06280716 A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis completed 2026-07-16 NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT06700499 A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis completed 2025-09-11 NCT06631170 Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis completed 2025-07-13 NCT05911841 A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis terminated 2025-03-14 Stop reason on the record: “The decision to terminate the study was due to efficacy/effectiveness reasons.”	2026-07-16	6 NCT07230860 NCT05995964 NCT06552520 NCT06775860	97
22	Advanced Medical Research Sandy Springs, United States · 4 spellings merged	17 15 completed, 2 terminated	NCT05882877 NCT05704738 NCT04392154 6 trials with titles NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT05704738 A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) completed 2025-11-25 NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) completed 2025-04-22 NCT05372419 A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color completed 2025-02-17 NCT05369403 A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab completed 2025-02-05 NCT05932654 POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis completed 2024-09-18	2026-07-01	1 NCT05509023	90
23	Oregon Medical Research Center Portland, United States · 4 spellings merged	17 15 completed, 2 terminated	NCT05882877 NCT06881251 NCT03422822 6 trials with titles NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT06881251 A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) terminated 2026-04-07 Stop reason on the record: “Terminated: futility criteria met at interim efficacy analysis.” NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT06130566 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis completed 2025-11-13 NCT05633355 A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) completed 2025-07-31 NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) completed 2025-04-22	2026-07-01	2 NCT07783425 NCT06407934	95
24	Wiseman Dermatology Research Inc. Winnipeg, Canada · 5 spellings merged	17 15 completed, 2 terminated	NCT05882877 NCT03422822 NCT06238817 6 trials with titles NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) terminated 2026-07-01 Stop reason on the record: “Sponsor Decision” NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT06238817 A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis completed 2025-10-17 NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) completed 2025-04-22 NCT05911841 A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis terminated 2025-03-14 Stop reason on the record: “The decision to terminate the study was due to efficacy/effectiveness reasons.” NCT05724199 A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) completed 2024-12-04	2026-07-01	1 NCT05995964	93
25	Center for Clinical Studies Webster, United States · 5 spellings merged	17 14 completed, 3 terminated	NCT03422822 NCT04392154 NCT05911841 6 trials with titles NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis completed 2025-12-22 NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) completed 2025-04-22 NCT05911841 A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis terminated 2025-03-14 Stop reason on the record: “The decision to terminate the study was due to efficacy/effectiveness reasons.” NCT05932654 POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis completed 2024-09-18 NCT05571943 A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis completed 2024-07-31 NCT04626297 A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) completed 2022-09-30	2025-12-22	2 NCT06727552 NCT06397911	88

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Atopic dermatitis: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Jianzhong Zhang Peking University People's Hospital	6	NCT06477835 NCT06277765 NCT06277245 NCT05667623 NCT05265923	PMID 42928785 MedComm, 2026 · High match PMID 42923801 Rheumatology and immunology research, 2026 · High match PMID 42880197 The Journal of pharmacology and experimental therapeutics, 2026 · High match
2	Qian jin Lu Chinese Academy of Medical Sciences Hospital of Skin Disease	4	NCT06891040 NCT05997927 NCT04539639 NCT04435392	PMID 39080181 BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2024 · High match
3	Lin Ma Beijing Children's Hospital	2	NCT06324812 NCT05650320	PMID 42767466 Journal of the American Academy of Dermatology, 2026 · High match PMID 42668711 Pediatric investigation, 2026 · High match
4	Ben Ehst Oregon Medical Research Center	2	NCT05439941 NCT05121480	PMID 42825999 Dermatology and therapy, 2026 · High match
5	Emma Guttman MOUNT SINAI HOSPITAL	2	NCT04605094 NCT03359356	PMID 42374848 Dermatitis : contact, atopic, occupational, drug, 2026 · High match PMID 41673463 Molecular psychiatry, 2026 · High match PMID 39251029 Journal of the American Academy of Dermatology, 2024 · High match
6	Aleksandra Stjepanovic Almirall, S.A.	1	NCT05916365	No paper matched at High or Medium confidence
7	Cheng Zhou Peking University People's Hospital	1	NCT06477835	PMID 42744271 International journal of biological macromolecules, 2026 · Medium match PMID 42237357 Journal of nanobiotechnology, 2026 · High match PMID 42221048 Intractable & rare diseases research, 2026 · High match
8	Peter Schmid-Grendelmeier University of Zurich	1	NCT05378698	No paper matched at High or Medium confidence
9	Joaquin Espinosa Linda Crnic Institute, University of Colorado Anschutz Medical Campus	1	NCT04246372	No paper matched at High or Medium confidence
10	Furen zhang Dermatology Hospital of Shandong First Medical University	1	NCT06058000	PMID 42761385 JAAD international, 2026 · High match PMID 42744774 Nature communications, 2026 · High match PMID 42601941 Frontiers in immunology, 2026 · High match

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.